-+ 0.00%
-+ 0.00%
-+ 0.00%

Dicot Pharma starts Phase 2b trial of LIB-01 for erectile dysfunction

PUBT·11/18/2026 06:05:44
Listen to the news
Dicot Pharma starts Phase 2b trial of LIB-01 for erectile dysfunction
  • Dicot Pharma initiated a Phase 2b trial of LIB-01 for erectile dysfunction on November 18, 2026.
  • The U.S. and European study will enroll at least 200 participants to guide dose selection for Phase 3 through repeated monthly dosing.
  • An initial stage will determine the highest dose for subsequent testing; completion is expected in the first quarter of 2027.
  • Results will be generated by the trial; earlier Phase 2a findings demonstrated proof of concept.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dicot Pharma AB published the original content used to generate this news brief on November 18, 2026, and is solely responsible for the information contained therein.